Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13863668 | 0.91 | TSHR (0.41) | TSHRPTGS2PTGS1MAPTLMNA | |
| SCHEMBL13979203 | 0.83 | PTGS2 (0.39) | PTGS2PTGS1 | |
| SCHEMBL30053669 | 0.83 | PTGS2 (0.38) | TSHRPTGS2PTGS1MAPT | |
| SCHEMBL13685896 | 0.81 | PTGS2 (0.39) | PTGS2PTGS1SLC1A1LMNAMEN1 | |
| SCHEMBL5154159 | 0.81 | PTGS2 (0.37) | PTGS2PTGS1 | |
| SCHEMBL23927587 | 0.81 | PTGS2 (0.39) | PTGS2PTGS1SLC1A1LMNAMEN1 | |
| SCHEMBL5151084 | 0.81 | PTGS2 (0.37) | PTGS2PTGS1 | |
| SCHEMBL4587231 | 0.80 | PTGS2 (0.38) | PTGS2PTGS1 | |
| SCHEMBL4587252 | 0.80 | PTGS2 (0.38) | PTGS2PTGS1 | |
| SCHEMBL17369721 | 0.79 | PTGS2 (0.36) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | VIVAVISION (SHANGHAI) LTD (CN) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | ROCK1, NOS1, ROCK2 | TSHR 1944/4885PTGS2 945/4885PTGS1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.